C75 trans

製品コードS8915 バッチS891501

印刷

化学情報

Synonyms

trans-C75, (±)-C75

Storage
(From the date of receipt)

3 years -20°C powder

化学式

C₁₄H₂₂O₄

分子量

254.32

CAS No.

191282-48-1

Solubility (25°C)*

体外

DMSO

51 mg/mL (200.53 mM)

Ethanol

26 mg/mL (102.23 mM)

Water

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	C75 trans (trans-C75, (±)-C75) is a novel, potent synthetic inhibitor of fatty acid synthase (FAS/FASN) with IC50 of 35 μM and 50 μM in clonogenic assays and spheroid growth assay, respectively. C75 is used as a tool for studying fatty acid synthesis in metabolic disorders and cancer.
in vitro	C75 is toxic to prostate cancer cells. C75 reduces cell migration, while enhances radiation-induced clonogenic kill and enhances the spheroid growth delay induced by radiation exposure. Apoptosis induction by radiation exposure is enhanced by C75 treatment.^[1] C75 inhibits fatty acid synthesis and growth of established cancer cell lines from neu-N transgenic mice. C75 reduces the proliferation and expression of FAS, neu, and related genes in mammary epithelium.^[2]
in vivo	C75 inhibits fatty acid synthesis and in vivo mammary cancer development. C75 treatment prevents mammary cancer development and retards mammary development in neu-N transgenic mice.^[2]

プロトコル(参考用のみ)

細胞アッセイ	細胞株	PC3 cells, LNCaP cells
	濃度	5 μM, 25 μM, 35 μM, 50 μM
	反応時間	3 h, 6 h, 24 h
	実験の流れ	PC3 cells are seeded in 25 cm² flasks at 10⁵ cells/flask. When cultures are in exponential growth phase, media is removed and replaced with fresh drug-containing media. Cells are then incubated for 24 h at 37℃ in 5% CO₂. To determine optimal sequencing of therapeutic agents, three different combination treatment schedules are assessed: 1. radiation and C75 administered simultaneously; 2. radiation administered 24 h before C75; and 3. radiation administered 24 h after C75. After treatment, cells are seeded for clonogenic survival assay.
動物実験	動物モデル	neu-N transgenic mice, FVB/N mice
	投薬量	30mg/kg
	投与方法	IP

参考

https://pubmed.ncbi.nlm.nih.gov/26484401/
https://pubmed.ncbi.nlm.nih.gov/15489885/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Sex differences in the neuroinflammatory signaling pathway: effect of miRNAs on fatty acid synthesis in microglia [ Biol Sex Differ, 2025, 16(1):9]	PubMed: 39905477
Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma [ Signal Transduct Target Ther, 2022, 7(1):46]	PubMed: 35169126
Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication [ Nat Metab, 2021, 10.1038/s42255-021-00479-4]	PubMed: 34580494

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。